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Abstract Aminopeptidase N (APN) is a zinc metallopeptidase
involved in the inactivation of biologically active peptides. The
knowledge of its precise distribution is crucial to investigate its
physiological role. This requires the use of appropriate probes
such as the recently developed highly potent and selective
radiolabeled APN inhibitor 2(S)-benzyl-3-[hydroxy(1P(R)-ami-
noethyl)phosphinyl]propanoyl-L-3-[125I]iodotyrosine ([125I]RB
129). Its binding properties were investigated using rat brain
homogenates (Kd = 3.4 nM) or APN expressed in COS-7 cells
(Kd = 0.9 nM). The specific binding was 95% at [Kd], and
preliminary autoradiography in intestine is promising. The
decreased affinity of [125I]RB 129 ( = 1036 M) for the E350D
APN mutant, supports the critical role of E350 in the amino-
exopeptidase action of APN.
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1. Introduction
Aminopeptidase N (APN; EC 3.4.11.2) is a membrane-
bound zinc metallopeptidase involved in the extracellular me-
tabolism of biologically active peptides. APN is expressed in
many tissues, with highest levels in intestinal and kidney brush
border membranes [1], but also found in lower quantity in
brain, lung, blood vessels, and primary culture of ¢broblasts
[2]. Furthermore, APN has been shown to be identical to
human lymphocyte surface cluster di¡erentiation antigen
CD13 [3], and has been reported to act as a major receptor
for transmissible gastroenteritis virus [4] and for human coro-
navirus 229E [5]. APN exhibits a broad speci¢city for peptides
with an N-terminal neutral or basic amino acid, and has been
shown to be involved in enkephalins and nociceptin catabo-
lism in the central nervous system [6,7] and to participate in
the enzymatic cascade of the renin-angiotensin system in brain
and peripheral organs by cleaving angiotensin III [8]. All these
¢ndings make this enzyme an interesting target for possible
therapeutic applications [9]. The knowledge of the precise dis-
tribution of APN is therefore crucial to investigate its phys-
iological role. Few studies on the localization of APN have
been done exclusively by using antibodies. In brain APN has
been reported to be essentially located on blood vessels [10^
12], a distribution which is hardly reconcilable with its peptide
metabolizing role. Radioactive inhibitors have the advantage
over antibodies to label the active site quantitatively in all
tissues and species, and to reveal even low levels of a biolog-
ical target [13]. However, it is essential to verify that the
labeled inhibitor has a good a⁄nity and is speci¢c for the
enzyme, as zinc metallopeptidases have many active site fea-
tures in common [14]. Another advantage of radioactive in-
hibitors is that their in vivo distribution can easily be followed
after di¡erent routes of administration [15], an important fac-
tor, considering the potential clinical applications of such
molecules.
We have recently described the ¢rst highly potent and se-
lective APN inhibitor which belongs to the class of K-amino-
phosphonic compounds [16,17]. Due to its nanomolar inhib-
itory potency towards APN and its selectivity versus other
metallopeptidases of the same family, RB 129 (2(S)-benzyl-
3-[hydroxy(1P(R)-aminoethyl)phosphinyl]propanoyl-L-3-iodo-
tyrosine) has been radiolabeled [18] to carry out a complete
characterization of the biochemical and pharmacological
properties of APN. In this paper we report the binding prop-
erties of this radiolabeled inhibitor on the rat brain mem-
branes, recombinant APN and one of its mutants expressed
in COS-7 cells [19].
2. Materials and methods
2.1. Rat brain membrane preparations
Rat brains minus cerebellum were homogenized in 10 vol of 50 mM
Tris^HCl pH 7.4, and centrifuged at 1000Ug for 10 min. The super-
natant was then centrifuged at 100 000Ug for 40 min. The pellet was
resuspended in 50 mM Tris^HCl bu¡er, pH 7.4 containing 0.02%
bacitracin. Binding assays were performed in the same bu¡er in a
¢nal volume of 1 ml containing 0.4^0.6 mg of protein and the iodi-
nated ligand.
2.2. Expression of recombinant pig APN
Recombinant pig APN was expressed in COS-7 cells. The plasmid
used contained the full-length cDNA encoding pig APN inserted into
an expression vector pcDNA3 (Invitrogen). The APN mutant E350A
was obtained by double-strand mutagenesis using the Transformer1
Site Directed Mutagenesis kit (Stratagene) following the manufactur-
er’s instructions. The presence of the expected mutation and the ab-
sence of non-speci¢c mutations were con¢rmed by sequencing the
complete coding sequence [19].
COS-7 cells were grown in Dulbecco’s modi¢ed Eagle’s medium
complemented with 10% fetal calf serum and 10U106 cells were trans-
fected with 50 Wg of plasmid by electroporation (250 V and 1000
microfarads, Biorad electroporator). Each pool of transfected cells
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was incubated in a 10 cm Petri dish at 37‡C for 48 h. The cells were
then washed twice and harvested by scraping in phosphate-bu¡ered
saline. After rapid centrifugation at 2000Ug, the cell pellet was resus-
pended in ice-cold 50 mM Tris^HCl, pH 7.4, and membranes were
prepared by homogenizing the cells in a Te£on-glass homogenizer
followed by centrifugation at 100 000Ug for 30 min at 4‡C. The ¢nal
membrane pellet was solubilized in 50 mM Tris^HCl, pH 7.4 contain-
ing 0.02% bacitracin. Binding assays were performed with 50^100 Wg
of protein/tube in a ¢nal volume of 1 ml.
2.3. Binding assays
Incubations were carried out at 35‡C and were terminated by ¢ltra-
tion through Whatman GF/B ¢lters. The ¢lters were rinsed twice with
5 ml of ice-cold bu¡er and the radioactivity was measured. For kinetic
studies [125I]RB 129 was used at 100 pM and dissociation was initiated
by addition of 1 WM cold iodinated ligand RB 129 after a 120 min
incubation. For saturation studies, incubations were for 80 min and
the radioactive ligand was used from 0.075 nM to 8 nM. For com-
petition experiments a ¢xed concentration of 10 pM [125I]RB 129 was
used in presence of various concentrations of di¡erent APN inhibi-
tors. Non-speci¢c binding was determined with 1 WM RB 129. More-
over, all experiments were performed in presence of thiorphan to
avoid non-speci¢c binding to NEP, for which the ligand has a Ki
value of 23.6 nM when tested in an enzymatic assay [17]. Competition
curves were analyzed, and kinetic and saturation binding parameters
were determined with the computer program EBDA. Ki values were
determined with the Cheng-Prussof equation: Ki = IC50/[1+(radioli-
gand concentration/Kd of the radioligand)].
2.4. Western blotting
Proteins from membranes of COS-7 cells were subjected to sodium
dodecyl sulfate^polyacrylamide gel electrophoresis and electroblotted
onto nitrocellulose ¢lters. The blots were rinsed with TBS-Tween 20
bu¡er then incubated with superblock blocking bu¡er (Pierce), anti-
serum raised against pig APN and ¢nally with an anti-mouse Ig,
horseradish peroxidase-linked antibody from sheep (Amersham
Corp.). Peroxidase activity was revealed with a chemoluminescent
detection kit from Amersham Corp. Puri¢ed pig APN was used as
a control to verify apparent molecular mass.
2.5. Autoradiography
After rat decapitation, the intestine was rapidly removed and frozen
in isopentane at 345‡C. Sections (16 Wm thick) were cut on a Bright
cryostat at 317‡C, thaw-mounted onto gelatin-coated slides, and
stored at 380‡C. All sections were warmed to room temperature
just prior to incubation with ligands. The slides were preincubated
for 30 min at room temperature in 50 mM Tris^HCl (pH 7.4), 16
mM saccharose, 0.2% BSA. Then slides were incubated with 1 nM
[125I]RB 129 in presence of thiorphan in 50 mM Tris^HCl (pH 7.4),
5 mM MgCl2 for 60 min at room temperature. For non-speci¢c bind-
ing, the slides were incubated as above but in presence of 1 WM of
cold RB 129. At the end of the incubation, the sections were washed
twice in ice-cold bu¡er for 10 min, followed by a rapid rinse in ice-
cold water and then dried under a cold airstream. Then, the ¢lms were
exposed for 3 days at 4‡C and developed.
2.6. Materials
The synthesis of RB 129 and of its 125I-radioiodinated analogue
were performed as previously described [17,18]. Thiorphan [20], Phe-
thiol [21,22] and the hydroxamate RB 38A N-[3(R)hydroxyaminocar-
bonyl)-2-benzyl-1-oxopropyl]-L-phenylalanine [23] used in this study
were prepared in the laboratory as previously described.
3. Results
3.1. General binding characteristics of [125I]RB 129
Total, speci¢c and non-speci¢c binding of [125I]RB 129 in-
creased linearly with the concentration of membrane protein
up to 2 mg/ml. At the ¢nal protein concentrations used rou-
tinely in the assay (between 0.4^0.6 mg/ml for the rat brain
membranes, and 50^100 Wg/ml for the recombinant APN), the
speci¢c binding of [125I]RB 129 was between 80^98% (not
shown).
3.2. Kinetic studies
The binding kinetics of [125I]RB 129 to rat brain mem-
branes appeared to follow a simple bimolecular reaction
with rates of both association and dissociation being mono-
phasic after transformation of the speci¢c binding data
(Fig. 1). Speci¢c [125I]RB 129 (100 pM) binding reached equi-
librium after 80 min incubation at 35‡C, and remained con-
stant for a further 200 min.
Association data were transformed according to the pseu-
do-¢rst-order rate equation on the basis that only V10% of
added ligand was bound at equilibrium. The data were re-
solved into a single-exponential function from which the asso-
ciation rate constant, k1, was calculated as 94.7U106 M31
min31.
The rate of dissociation of [125I]RB 129 was also resolved
into a single-exponential function when the speci¢c binding
data were transformed according to the ¢rst-order rate reac-
tion, from which the dissociation rate constant (k31) was cal-
culated as 0.022 min31. The kinetically derived dissociation
constant (kd = k31/k1) was 0.23 nM.
Fig. 1. Kinetic analysis of speci¢c [125I]RB 129 (100 pM) binding to
rat brain membranes at 35‡C. A: Time course association of
[125I]RB 129 binding. Inset: Transformation of association data ap-
propriate for pseudo-¢rst-order conditions. B: Time course of disso-
ciation of [125I]RB 129 binding initiated with 1 WM unlabeled RB
129. Inset: Transformation of speci¢c binding data according to the
¢rst-order dissociation rate equation.
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3.3. Saturation binding analysis
In both rat brain membranes and recombinant APN,
[125I]RB 129 demonstrated saturable, high a⁄nity binding to
an apparent single population of non-interacting sites when
the non-speci¢c binding was de¢ned as the amount of radio-
ligand remaining in the presence of 1 WM unlabeled RB 129
(Fig. 2). The equilibrium dissociation constant (Kd) and max-
imal capacity of binding sites (Bmax) obtained from the speci¢c
binding data were 3.4 þ 0.3 nM and 722 þ 88 fmol/mg of pro-
tein, respectively, in the rat brain homogenates, and 0.9 þ 0.2
nM and 650 þ 67 fmol/mg of protein, respectively, in the re-
combinant APN wild-type. No speci¢c binding was measured
on the E350A mutated APN (Fig. 2). The presence of the
mutated enzyme was veri¢ed by Western blot (data not
shown).
3.4. Competition studies
All unlabeled inhibitors (compound 1, RB 129, RB 38A,
Phe-thiol) produced a concentration-dependent inhibition of
speci¢c [125I]RB 129 binding to membranes prepared from
both rat brain and transfected COS-7 cells. Moreover, a
rather good correlation between the e⁄ciency of these com-
pounds to inhibit [125I]RB 129 binding and their inhibitory
Fig. 2. Saturation analysis and Scatchard transformation (inset) of
[125I]RB 129 binding to rat brain membranes (A) and recombinant
APN (b represents the speci¢c binding of [125I]RB 129 to the wild-
type, and E speci¢c binding to the mutant E350D) expressed in
COS-7 cells (B). Non-speci¢c binding to each tissue was de¢ned
with 1 WM unlabeled RB 129.
Fig. 3. Competition between [125I]RB 129 and increasing concentra-
tions of compound 1, RB 129, RB 38A, Phe-thiol for APN in rat
brain membranes (A) and COS-7 cells in which recombinant wild-
type APN has been transfected (B).
Fig. 4. Radioautography of rat intestine showing the speci¢c bind-
ing of 1 nM [125I]RB 129 on APN localized in the intestinal mem-
branes. A complete absence of binding was observed in presence of
1 WM unlabeled RB 129.
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potency towards APN, determined in previous enzymatic ex-
periments, was obtained, except for the hydroxamate RB 38A
and the Phe-thiol inhibitors in the rat brain membranes
[17,21,22,24] (Table 1). The competition curves were mono-
phasic, and the slope values were always not signi¢cantly
di¡erent from unity (Fig. 3).
3.5. Autoradiography of rat intestinal APN
Fig. 4 shows the distribution of APN labeled with [125I]RB
129. Staining of intestine was absent in the controls which
were incubated in presence of the same concentration of ra-
dioiodinated inhibitor (1 nM) and an excess of cold ligand.
Speci¢c binding of [125I]RB 129 was observed in the circular
layer of the intestine.
4. Discussion
RB 129 is the ¢rst highly potent and selective APN inhib-
itors which has been described [17]. In this study we have
characterized the binding of its radioiodinated form,
[125I]RB 129, using either rat brain membranes or recombi-
nant APN expressed in COS-7 cells. The binding was tissue
concentration dependent, reversible and saturable. Saturation
analysis indicated that [125I]RB 129 binds with high a⁄nity to
a homogeneous population of non-interacting sites in rat
brain membranes and COS-7 cells transfected with APN
wild-type. Thus, Scatchard plots were linear, and Hill plots
had slopes which were not signi¢cantly di¡erent from unity.
From rat brain homogenates [125I]RB 129 bound to a single
class of binding sites with a Kd value of 3.4 nM and a Bmax of
722 fmol/mg of protein. Speci¢c binding was high, being al-
most 95% at the Kd value. In binding studies using recombi-
nant APN expressed in COS-7 cells [125I]RB 129 had a Kd of
0.9 nM and again a high speci¢c binding (V92% at the Kd
value). Recently, E350 has been characterized as a critical res-
idue involved in the N-terminal amine binding site of APN
[19]. The mutation E350A led to a non-measurable speci¢c
binding. This result was expected, as E350 is essential to sta-
bilize aminophosphinic inhibitors in the S1 subsite, and the
binding data are in good agreement with the enzymatic assay
demonstrating that this mutated APN shows an activity at
least 10 000-fold lower than that of the wild-type APN [19].
This reinforces the argument that E350, found highly con-
served in zinc metallopeptidase by sequence comparison, in-
teracts with the amino group of substrates and inhibitors and
participates to the exopeptidase speci¢city of aminopepti-
dases.
Strikingly, displacement of the radiolabeled APN inhibitor
Table 1
Ki values (nM) of inhibitors determined in binding studies on rat brain membranes and recombinant APN expressed in COS-7 cells or deter-
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from rat brain membranes by increasing concentration of RB
38A or Phe-thiol inhibitors yielded Ki values of 1618 nM and
203 nM, respectively, which were very di¡erent to the Ki val-
ues obtained in enzymatic studies in which pure porcine APN
is used (Ki = 120 nM and 12.1 nM, respectively) [21^23]. These
more than 10- and 15-fold lower a⁄nities of both inhibitors
observed in binding studies are very likely due to the lower
selectivity of RB 38A and Phe-thiol inhibitors for APN as
compared to the aminophosphinic inhibitors in regard to
the various other aminopeptidases present in rat brain mem-
branes. This is strongly supported by the results obtained with
the recombinant APN expressed in COS-7 cells, which could
be considered as a partially puri¢ed enzyme preparation.
Thus, Phe-thiol inhibitor inhibited the [125I]RB 129 binding
on COS-7 cell membranes transfected with APN with Ki value
of 7.7 nM which parallels that found in enzymatic assay
(Ki = 12.1 nM).
The iodinated APN inhibitor [125I]RB 129 was synthesized
(i) to determine the level of membrane-bound APN in di¡er-
ent brain regions after various pharmacological treatments
[25^28]; (ii) to perform a localization of the enzyme in the
central nervous system and at the periphery of di¡erent spe-
cies. The use of such an inhibitor for autoradiography has
advantages over enzymatic assay which is very imprecise or
immunological methods for which quantitation could be ham-
pered by di¡erences in the tertiary structure and epitope pre-
sentation of the enzyme in various tissues, as shown in the
case of angiotensin converting enzyme [29,30]. Furthermore,
although the primary sequences of APN from di¡erent species
are highly conserved [4,31^34], it cannot be excluded that the
enzyme appears to be di¡erentially glycosylated not only in
di¡erent species but also in di¡erent tissues of the same spe-
cies, as already observed for neprilysin, another zinc metal-
lopeptidase (NEP) [35], which might a¡ect its recognition.
Moreover, the use of 125I needs only short exposure times
to obtain autoradiograms, and due to its high speci¢c activ-
ity o¡ers the possibility of a precise visualization of the en-
zyme in various tissues. As a preliminary experiment, we have
visualized APN in the rat intestine with [125I]RB 129 and
found a distribution at the level of the brush border in
good agreement with previous studies reporting immunolabel-
ing of APN in intestinal membranes, where its physiological
function appears to be the hydrolysis of dietary peptides
[36,37].
In conclusion, the highly potent and selective APN inhib-
itor [125I]RB 129, is an excellent ligand for binding studies that
could be easily automatized for a high throughput screening,
and autoradiography, and could allow the direct detection of
nanogram quantities of the enzyme from tissue extracts, as
already shown with [125I]RB 104, a potent inhibitor of NEP
[21,22]. Furthermore, this radiolabeled compound could be
modi¢ed to generate new dual inhibitors of NEP and APN,
which both are involved in enkephalin degradation, o¡ering
the possibility to follow its bioavailability after di¡erent
routes of administration, an important factor considering
the potential clinical application of such molecules (review
in [9]). In vivo displacement could also be performed to study
the physiological modulation of enkephalin pathways by
others neuromodulators.
Acknowledgements: This work was supported by grants from Synthe-
labo Recherche, and European Community (BMH4 CT98 2267).
References
[1] Maroux, S., Louvard, D. and Baratti, J. (1973) Biochim. Bio-
phys. Acta 321, 282^295.
[2] Sanderink, G.J., Artur, Y. and Siest, G. (1988) J. Clin. Chem.
Clin. Biochem. 26, 795^807.
[3] Look, A.T., Ashmun, R.A., Shapiro, L.H. and Peiper, S.C.
(1989) J. Clin. Invest. 83, 1299^1307.
[4] Delmas, B., Gel¢, J., Kut, E., Sjostrom, H., Noren, O. and
Laude, H. (1994) J. Virol. 68, 5216^5224.
[5] Yeager, C.L., Ashmun, R.A., Williams, R.K., Cardellichio, C.B.,
Shapiro, L.H., Look, A.T. and Holmes, K.V. (1992) Nature 357,
420^422.
[6] Waksman, G., Bouboutou, R., Devin, J., Bourgoin, S., Cesselin,
F., Hamon, M., Fournie¤-Zaluski, M.C. and Roques, B.P. (1985)
Eur. J. Pharmacol. 117, 233^243.
[7] Montiel, J.L., Cornille, F., Roques, B.P. and Noble, F. (1997)
J. Neurochem. 68, 354^361.
[8] Zini, S., Fournie¤-Zaluski, M.C., Chauvel, E., Roques, B.P., Cor-
vol, P. and Llorens-Cortes, C. (1996) Proc. Natl. Acad. Sci. USA
93, 11968^11973.
[9] Roques, B.P., Noble, F., Dauge¤, V., Fournie¤-Zaluski, M.C. and
Beaumont, A. (1993) Pharmacol. Rev. 45, 87^146.
[10] Hersh, L.B., Aboukhair, N. and Watson, S. (1987) Peptides 8,
523^532.
[11] Turner, A.J., Hooper, N.M. and Kenny, A.J. (1987) in: Mam-
malian Ectoenzymes (Kenny, A.J. and Turner, A.J., Eds.), pp.
211^248, Elsevier Science Publisher, Amsterdam.
[12] Solhonne, B., Gros, C., Pollard, H. and Schwartz, J.C. (1987)
Neuroscience 22, 225^232.
[13] Zajac, J.M., Gacel, G., Dodey, P., Fournie¤-Zaluski, M.C., Ro-
ques, B.P., Roy, J., Morgat, J.L., Chaillet, P., Collado, H., Cost-
entin, J., Petit, F. and Rossignol, P. (1983) in: Phencyclidine and
Related Arylcyclohexylamines: Present and Future Applications
(Kamenka, J.M., Domino, E.F. and Geneste, P., Eds.), pp. 143^
152, NPP Books, Ann Arbor.
[14] Matthews, B.W. (1988) Acc. Chem. Res. 21, 333^340.
[15] Sales, N., Dutriez, I., Mazie're, B., Ottaviani, M. and Roques,
B.P. (1991) Regul. Pept. 33, 209^222.
[16] Chen, H., Noble, F., Coric, P., Fournie¤-Zaluski, M.C. and Ro-
ques, B.P. (1998) Proc. Natl. Acad. Sci. USA 95, 12028^12033.
[17] Chen, H., Roques, B.P. and Fournie¤-Zaluski, M.C. (1999) Bio-
org. Med. Chem. Lett. 9, 1511^1516.
[18] Chen, H., Bischo¡, L., Fournie¤-Zaluski, M.C. and Roques, B.P.
(1999) J. Lab. Comp. Radiopharm., in press.
[19] Luciani, N., Marie-Claire, C., Ru¡et, E., Beaumont, A., Roques,
B.P. and Fournie¤-Zaluski, M.C. (1998) Biochemistry 37, 686^
692.
[20] Roques, B.P., Fournie¤-Zaluski, M.C., Soroca, E., Lecomte, J.M.,
Malfroy, B., Llorens, C. and Schwartz, J.C. (1980) Nature 288,
286^288.
[21] Fournie¤-Zaluski, M.C., Coric, P., Turcaud, S., Bruetschy, L.,
Lucas, E., Noble, F. and Roques, B.P. (1992) J. Med. Chem.
35, 1259^1266.
[22] Fournie¤-Zaluski, M.C., Soleilhac, J.M., Turcaud, S., La|«-Kuen,
R., Crine, P., Beaumont, A. and Roques, B.P. (1992) Proc. Natl.
Acad. Sci. USA 89, 6388^6392.
[23] Schmidt, C., Peyroux, J., Noble, F., Fournie¤-Zaluski, M.C. and
Roques, B.P. (1991) Eur. J. Pharmacol. 192, 253^262.
[24] Bouboutou, R., Waksman, G., Devin, J., Fournie¤-Zaluski, M.C.
and Roques, B.P. (1984) Life Sci. 35, 1023^1030.
[25] van Hal, P.T., Hopstaken-Broos, J.P., Prins, A., Favaloro, E.J.,
Huijbens, R.J., Hilvering, C., Figdor, C.G. and Hoogsteden,
H.C. (1994) J. Immunol. 153, 2718^2728.
[26] Vahdat, L., Maslak, P., Miller, W.H., Eardley, A., Heller, G.,
Scheinberg, D.A. and Warrell, R.P. (1994) Blood 84, 3843^3849.
[27] Kehlen, A., Gohring, B., Langner, J. and Riemann, D. (1998)
Clin. Exp. Immunol. 111, 435^441.
[28] Phillips, A.J., Tomasec, P., Wang, E.C., Wilkinson, G.W. and
Borysiewicz, L.K. (1998) Virology 250, 350^358.
[29] Jackson, B., Cubela, R. and Johnston, C.I. (1986) Aust. J. Exp.
Biol. Med. Sci. 64, 149^155.
[30] Strittmatter, S.M. and Snyder, S.H. (1987) Neuroscience 21, 407^
420.
[31] Olsen, J., Cowell, G.M., Konigshofer, E., Danielsen, E.M., Mol-
FEBS 23075 28-1-00
F. Noble et al./FEBS Letters 467 (2000) 81^86 85
ler, J., Laustsen, L., Hansen, O.C., Welinder, K.G., Engberg, J.,
Hunziker, W., Spiess, M., Sjo«stro«m, M. and Noren, O. (1988)
FEBS Lett. 238, 307^314.
[32] Malfroy, B., Kado-Fong, H., Gros, C., Giros, B., Schwartz, J.C.
and Hellmiss, R. (1989) Biochem. Biophys. Res. Commun. 161,
236^241.
[33] Watt, V.M. and Yip, C.C. (1989) J. Biol. Chem. 264, 5480^5487.
[34] Yang, X.F., Milhiet, P.E., Gaudoux, F., Crine, P. and Boileau,
G. (1993) Biochem. Cell Biol. 1993, 278^287.
[35] Relton, J.M., Gee, N.S., Matsas, R., Turner, A.J. and Kenny,
A.J. (1983) Biochem. J. 1983, 519^523.
[36] Sjo«stro«m, N., Noren, O., Jeppesen, L., Staun, M., Svensson, B.
and Christiansen, L. (1978) J. Biochem. 88, 503^511.
[37] Terashima, H., Wong, H., Kobayashi, R. and Bunnett, N.W.
(1992) Gastroenterology 102, 1867^1876.
FEBS 23075 28-1-00
F. Noble et al./FEBS Letters 467 (2000) 81^8686
